Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of BAY 2327949 on Renal Perfusion in Moderate Chronic Kidney Disease
NCT04552262Phase 1Terminated
- Sponsor
- Bayer
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enuvaptan in chronic kidney disease (CKD) (2 arms), sponsored by Bayer. Primary endpoint: Difference between renal medullary perfusion after administration of BAY 2327949 and placebo at 2 hours. Started Sep 2020; status: terminated.
02
Drugs
enuvaptan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04552262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552262.